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Background: Electrochemotherapy (ECT) is increasingly used in the treatment of primary 
and secondary skin tumors, but little is known about the pathologic mechanism responsible 
for tumor cell destruction in humans. Knowledge of detailed mechanism of host response after 
ECT may improve the treatment efficacy related to patient selection and technique refinements.
Aim: The aim of the study was to investigate the histopathology and mechanism of cell death 
after ECT in cutaneous melanoma metastases. 
Methods: Skin biopsy specimens were sequentially obtained after ECT of cutaneous melanoma 
metastases, during a follow-up period of 2 months. Results from histologic evaluation and 
immunohistochemical characterization of the inflammatory infiltrate (CD3, CD4, CD8, CD56, 
Granzyme-B) were compared with a panel of apoptosis-related markers.
Main outcome measures: Evidence of the mechanism of tumor cell damage, identification 
of histological and immunohistochemical signs of apoptosis and/or necrosis underlining a pos-
sible time course of tumor destruction and inflammatory reaction after ECT.
Results: Early signs of epidermal degeneration, an increase of the inflammatory infiltrate, 
and initial tumor cell morphological changes were already detected 10 min after ECT. The cell 
damage progression, as demonstrated by histological and immunohistochemical evidence using 
apoptotic markers (TUNEL and caspase-3 staining), reached a climax 3 days after treatment, to 
continue until 10 days after. Scarring fibrosis and complete absence of tumor cells were observed 
in the late biopsy specimens. A rich inflammatory infiltrate with a prevalence of T-cytotoxic 
CD3/CD8-positive cells was detected 3 h after ECT and was still appreciable 3 months later.
Conclusion: This study attempts to define the time course and characteristics of tumor response 
to ECT. The observations suggest both a direct necrotic cell damage and a rapid activation 
of apoptotic mechanisms that occur in the early phases of the cutaneous reaction to ECT. A 
persistent immune response of T-cytotoxic lymphocytes could possibly explain the long-term 
local tumor control.
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Introduction
Electrochemotherapy (ECT) is a tumor ablation modality that combines cell membrane 
electroporation (EP) and low dosage administration of cytotoxic drugs.1 Since the early 
1990s, ECT has emerged as a local treatment for superficial tumors. The efficacy of ECT 
was initially demonstrated in the treatment of head and neck cancers,2 and a number of 
investigations demonstrated its effectiveness in the treatment of several types of nodular 
tumor of different histology.3,4 In 2006, the multicentric European Standard Operating 
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Procedures of ECT study established the standard operat-
ing procedures for ECT use in the clinic.1 Currently, ECT is 
employed for cutaneous or subcutaneous tumor nodules of any 
type of cancer, both primary and metastatic, and as a palliative 
treatment in case of tumor bleeding or for alleviation of disease-
related pain. ECT can also be applied as an organ-sparing 
treatment of non-operable primary or recurrent tumors, as 
well as a neoadjuvant therapy before conventional approach.5–9
The technique is based on the controlled local delivery of 
short and intense electric pulses that reversibly permeabilize 
the cell membrane barrier (EP), allowing non-permeant or 
low-permeant anticancer drugs (usually bleomycin) to enter 
the tumor cells, without affecting the surrounding normal 
or electrically unexposed tissues.1 Due to its mechanism of 
action, ECT selectively kills tumor cells without denaturing 
proteins. It has been proposed that ECT might allow tumor 
antigen shedding and local inflammation, thus attracting 
immune antigen-presenting cells. Therefore, an antitumor 
immune response, triggered by the tumor cell death, may 
contribute to the disease control.10–12 Even if the clinical 
response to ECT has now been proved on several types of 
skin tumors, both in humans and in animal models, still very 
little is known about the tissue response to ECT in vivo. This 
study aimed at investigating the tissue changes that occur 
after ECT in cutaneous melanoma metastases. Sequential 
biopsies were taken from treated tumor tissue. Cell damage 
and inflammatory response to ECT were evaluated through 
histological and immunohistochemical analysis, using 
inflammatory and apoptotic-related markers.
Methods
Patients
This study was conducted at the Dermatology Clinic, 
 University of Modena and Reggio Emilia. Two patients with 
stage IIIc melanoma with multiple cutaneous metastases were 
selected and ECT was offered. Written informed consent was 
obtained before treatment. The Ethical committee of Modena 
approved this study. The first patient was a 79-year-old 
woman who had underwent surgery for a primary melanoma 
of the left foot, with regional lymph node metastases, 2 years 
before undergoing ECT. The patient had several months’ his-
tory of recurrent multiple cutaneous metastases located at the 
left lower limb. The second patient was a 91-year-old woman 
with a history of primary subungual melanoma of the right 
fifth toe and multiple in-transit cutaneous metastases located 
at the right leg. In both the patients, ECT was chosen as a 
palliative approach to control the high number and the recur-
rent character of the lesions. All visible or palpable lesions in 
both the patients were treated in a single ECT session. Target 
lesions consisted of multiple, single or grouped, firm papules 
and nodules of different sizes. 
ECT treatment
Both the patients were treated under spinal anesthesia. 
Because of the high number of tumor nodules, intravenous 
administration of bleomycin (15,000 IU/m2 in bolus) was 
preferred to intralesional injection. Square wave electric 
pulses (8 pulses of 1000 V/cm amplitude, 100 µs duration 
at 5000 Hz repetition frequency) were generated and deliv-
ered to the tumor nodules using an electric pulse generator 
(Cliniporator; IGEA SpA, Carpi, Italy), between 8 and 28 
min following bleomycin administration (an appropriate time 
window to successfully allow the maximum diffusion of the 
drug into the tissues). Complete EP of the tumor tissue was 
achieved through the insertion of a hexagonal array needle 
electrode to the nodules, including 1 cm safety margin. Elec-
tric pulses were applied after each insertion. The efficiency 
of the treatment was automatically checked and reported by 
the electroporator device. If necessary, several applications 
were performed to efficiently cover the entire tumor volume. 
After treatment, a dry dressing was applied. 
Biopsy specimens
Sequential punch biopsy specimens were obtained under local 
anesthesia from cutaneous tumor nodules before ECT and 
at 10 min, 3 h, 3 days, 10 days, 1 month, and 2 months after 
ECT. A total of 21 biopsies were processed. In the first patient, 
seven sequential biopsies were obtained from a single large 
nodule, whereas other seven sequential biopsies were taken 
from smaller adjacent lesions in order to minimize differences 
due to different anatomic sites. Seven sequential biopsies 
from separate adjacent lesions were taken from the right lower 
limb of the second patient. Routine histologic analysis was 
performed on formalin-fixed, paraffin-embedded, 5-µm-thick 
sections and stained with hematoxylin–eosin. 
Terminal Uridine deoxynucleotidyl 
transferase dUTP Nick End Labeling 
(TUNEL) staining
TUNEL staining was performed using a commercial kit 
(In Situ Cell Death Detection Kit; Roche Diagnostics 
GmbH, Basel, Switzerland) according to the manufac-
turer’s instructions. Briefly, after deparaffinization and 
rehydration, tissue sections were treated with 20 mg/mL 
proteinase K at room temperature for 30 min. They were 
then washed with phosphate-buffered saline (PBS) solution 
and incubated with TUNEL reaction, a solution formed by 
450 µL of Label Solution (fluorescein-labeled nucleotides) 
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and 50 µL of enzyme solution (terminal deoxynucleotidyl 
transferase) at 37°C for 60 min in the dark, then washed 
with PBS. Sections, mounted in buffered glycerin, were 
then analyzed using confocal microscopy (Leica TCS SP2 
with AOBS, Acoustic Opto Beam Splitter; Leica, Wetzlar, 
Germany).
Immunofluorescence
Caspase-3
Paraffin-embedded specimens were examined by indirect 
immunofluorescence reaction. After deparaffinization and 
rehydration, tissue sections were incubated using bovine 
serum albumin (BSA) 0.1%, then washed with PBS and 
incubated with antirabbit Caspase 3 active antibody (R&D 
System (Minneapolis, Minnesota USA), 1:150) at room 
temperature for 60 min. After washing with PBS and incuba-
tion with fluorescent antibody (antirabbit IgG, Alexa Fluor; 
Invitrogen, 1:200) at room temperature for 60 min, sections 
were counterstained with DAPI (0.1 mg/mL, Sigma-Aldrich, 
Saint Louis, Missouri, USA), included in buffered glycerin, 
and analyzed using confocal microscopy.
Immunohistochemistry
The immunohistochemical characterization of the inflam-
matory infiltrate was performed with the following anti-
body panel: mouse monoclonal antihuman-CD20 (ab9475, 
Abcam, Cambridge, UK, 1:100); rabbit polyclonal antihu-
man CD3 (ab5690, Abcam 1:150); mouse monoclonal 
antihuman CD4 (ab846, Abcam 1:100); mouse monoclonal 
 antihuman CD8 (clone C8/144B; Dako, Glostrup, Denmark, 
1:100); mouse monoclonal antihuman CD56 (Dako, 1:100); 
antirabbit-HMB45 (polyclonal antibody; Thermo Scientific, 
Waltham, Massachusetts, USA, 1:200); rabbit polyclonal 
antihuman Granzyme-B (ab4059, Abcam 1:200). Briefly, 
sections were incubated for 5 min with a blocking solution 
(Ultra V Block; Laboratory Vision Corporation, Fremont, 
California, USA) to stop the endogenous peroxidase or alka-
line phosphatase activity. After washing, sections were incu-
bated with secondary biotinylated antibody (goat antimouse 
and antirabbit biotinylated antibody 1:100; BioSpa), and a 
streptavidin–biotin complex (streptavidin-biotinylated HRP 
1:100; BioSpa, Milan, Italy) with an automated immunos-
tainer (Benchmark; Ventana, Tucson, AZ, USA) was applied. 
Reaction products were finally stained with 3-amino-9-etil-
carbazole and counter-stained with Mayer’s hematoxylin to 
be visualized.
Results
Patient outcomes and tumor response
The treated lesions showed a progressive reduction of volume 
during the first weeks after ECT, due to gradual shrinkage 
and necrosis. At 2–3 months after treatment, the smaller 
tumor nodules were no longer detectable and replaced by 
slight dermal fibrosis. A partial response was also evident 
in the larger nodules that appeared markedly reduced in 
volume (Figure 1).
Treatment toxicity 
No adverse events occurred during or after the ECT treat-
ments. Postoperative pain was moderate, and analgesia was 
provided by paracetamol.
Figure 1 Clinical response of melanoma metastases after ECT (patient 1): (A) before treatment; (B) 3 days; (C) 10 days; (D) 1 month; (E) 2 months.
A B C D E
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Histologic findings
The histopathology findings were consistent, independently 
of the biopsy site. Ten minutes after ECT, early signs of dam-
age could already be detected including focal homogenization 
of the epidermis, increase of the inflammatory infiltrate and 
slight morphological alterations of tumor cells (homogeneous 
eosinophilic cytoplasm, chromatin clumping, and less promi-
nent nucleoli) (Figure 2, 1B and 2B). At 3 h time point, the 
tissue damage was readily evident. The epidermis showed 
diffuse spongiosis, detachment from the underlying dermis 
and foci of cell necrosis. The dermis showed conspicuous 
edema, along with a massive mononuclear inflammatory 
infiltrate surrounding and permeating the tumor nodules. 
Tumor cell damage was characterized by foci of swollen 
cells with marked chromatin clumping, nucleo-cytoplasmic 
vacuolization, and loosening of cell connections. Several 
syncytial aggregations were detected, surrounded by the 
mononuclear infiltrate (Figure 2, 1C and 2C). The inflamma-
tory response and the cell damage progressed at 3-day time, 
with marked nuclear deterioration, neoplastic cell fusion, 
and a massive inflammatory infiltrate permeating the tumor 
nodules (Figure 2, 2D). Scant signs of endothelial damage and 
fibrin deposition can be appreciated. At 10 days after ECT, 
advanced damage was detectable, consisting in shedding 
of the epidermal sheet, diffuse damage of the tumor cells 
with diffuse inflammatory infiltrate invading the tumor with 
multinuclear cell formation. The inflammatory mononuclear 
cells appeared extensively rimming the tumor cells as well 
as the degenerated cell remnants (Figure 2, 2E). 
At 1 month after ECT, epidermis was completely regen-
erated. The dermis showed compact fibrosis in its upper 
part, while in the deep dermis the ratio between tumor cells 
and inflammatory infiltrate was completely inverted, that is, 
few remaining mono- or multi-nucleated tumor cells – as 
highlighted with the HMB45 staining – were surrounded 
by a dense inflammatory infiltrate (Figure 2, 1F and 2F). At 
2 months, compact fibrosis and melanophages were present 
in the upper dermis, while few remaining inflammatory cells 
were present in the lower dermis. No tumor remnants were 
detected (Figure 2, 1G and 2G). The main histologic findings 
are summarized in Table 1.
TUNEL and activated caspase-3 staining
The TUNEL reaction showed a marked positivity 3 h after treat-
ment, peaking at 3 days, then returning toward base levels at 10 
days and 1 month, and completely disappearing after 2 months 
(Figure 2, 3B–G). This suggests that an early, transient activa-
tion of the apoptotic mechanisms takes place after treatment.
Caspase-3 immunostaining paralleled the TUNEL reac-
tion, confirming the occurrence of an apoptotic process 
Figure 2 Time course of histological and immunohistochemical changes in cutaneous melanoma metastases after ECT. Column (A) before treatment; (B) 10 min; (C) 3 h; 
(D) 3 days; (E) 10 days; (F) 1 month; (G) 2 months. Lines: 1 and 2: H&E; Line 3: TUNEL reaction; Line 4: caspase-3 staining. Line 1 original magnification 100×; Line 2 original 
magnification 250×.
Abbreviations: ECT, electro chemotherapy; H&E, hematoxylin–eosin; TUNEL, Terminal Uridine deoxynucleotidyl transferase dot Nick End Labeling; min, minutes; h, hours.
A
(1)
(2)
(3)
(4)
B C D E F G
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triggered by enzymatic activation. Activated caspase-3+ cells 
were detected in the tumor nodules 3 h after ECT. These cells 
increased at 3 and 10 days. After 1 and 2 months, caspase-3 
positivity was still appreciated in the cytoplasm of the mono/
multinucleated cells within the tumor mass (Figure 2, 4B–G).
Inflammatory infiltrate
The immunohistochemical analysis of the inflammatory infil-
trate showed a striking prevalence of CD3+ T lymphocytes 
in all stages of the tissue reaction after ECT. No CD20+ B 
cells were detected. The infiltrate consisted largely of CD8+ 
cells, whereas CD4+ lymphocytes were scant. In particular, 
the inflammatory cells rimming the tumor cells, both single 
and multinucleated, as well as the tumor cell remnants, 
were exclusively composed of CD8+ lymphocytes express-
ing Granzyme-B (Figure 3A and B). Foci of CD56+ (NK) 
cells were present, interspersed within the tumor nodules, 
beginning at 3 h and still detected at 1 month after treatment. 
These findings demonstrate that cytotoxic/suppressor cells 
are activated early after ECT treatment, are in close contacts 
with apoptotic tumor cells, and represent the key elements in 
the late inflammatory response. Results of the immunohisto-
chemical analysis are summarized in Table 1.
Discussion
Several clinical studies have demonstrated the safety and 
efficacy of ECT in the tumor control of a wide range of pri-
mary and metastatic malignancies.6–8,13 In particular, ECT has 
been shown to be a safe and effective treatment option in a 
palliative setting for melanoma cutaneous and subcutaneous 
metastases.14–16 Early studies showed that the ECT effective-
ness was linked to the combination of chemotherapeutic 
Table 1 Main histological and immunohistochemical findings after electrochemotherapy
Histology TUNEL Activated 
caspase-3
Infiltrate Tipization
10 Min Initial epidermal damage (homogenization, spongiosis)
Dermal and intratumoral edema
Peri- and intratumoral inflammatory infiltrate
Sparse morphological alterations in tumor cells 
(homogeneous eosinophilic cytoplasm, chromatin 
condensation)
Sporadic 
positive cells
Negative Not performed
3 H Focal epidermal necrosis, spongiosis, junctional 
detachment
Severe dermal edema
Marked increase of the peri- and intratumoral 
inflammatory infiltrate
Foci of degenerated tumor cells (homogeneous 
eosinophilic cytoplasm, chromatin condensation, 
onset of syncytial  aggregations)
Increase of 
positive cells
Increase of 
positive cells
Prevalence of CD3+, 
CD8+ cells
Foci of Granzyme-B+ 
and TIA-1+ cells
Isolated CD56+ cells
3 Days Progressive epidermal damage
Massive inflammatory infiltrate both peri- and 
intranodular with wreath-like disposition around 
multinucleate cells
Progression of degenerated tumor cell foci
Several syncytial aggregations
Extensive 
presence of 
positive cells in 
tumor nodules
Extensive presence of 
positive cells in tumor 
nodules
Increased prevalently 
CD8+ infiltrate with 
perinodular and 
pericellular disposition 
(rimming) 
Granzyme-B+ cells
Spare CD56+ cells
10 Days Epidermal necrosis
Massive inflammatory infiltrate
Several multinucleated tumor cells rimmed by 
lymphocytes
Initial fibrosis and vascular damage
Sporadic 
positive cells
Several positive cells CD8+ infiltrate with 
pericellular disposition 
(rimming)
Granzyme-B+ cells
1 Month Regenerated epidermis
Residual tumor cells in the deep dermis (HMB45+), 
with massive lymphocytic infiltrate
Increased fibrosis in the superficial dermis
Sporadic 
positive cells
Diffuse syncytial 
positive cells
Rich CD8+ infiltrate 
still affects few residual 
tumor cells
Granzyme-B+ cells
Spare CD56+ cells
2 Months Dermal fibrosis
Numerous melanophages
Complete disappearing of tumor cells
Residual focal lymphocytic infiltrate
Negative Negative Residual CD8+ 
infiltrate
Abbreviations: Min, minutes; H, hours.
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drug injection and locally applied electric pulses, because 
either component, alone, was ineffective. The effect of ECT 
on tumor tissue may be related to a combination of different 
components: the direct cell damage caused by the cytotoxic 
activity of bleomycin molecules that have entered the cell 
through the electroporated cell membrane and the indirect 
damage by vascular effects and/or immuno-inflammatory 
reactions.10,11,17 In vitro and in vivo studies suggested trig-
gering of apoptosis as a prevalent mechanism in the direct 
tumor cell damage.18,19 In humans, evidence of a prevalent 
mechanism operating in vivo is lacking. To highlight the 
pathways of ECT action in vivo, this study investigated the 
alterations in cutaneous melanoma metastases treated with 
ECT through sequential histologic and immunohistochemi-
cal analysis. The apoptotic markers caspase-3 and TUNEL 
were used along with histological evaluation. The results help 
to define the time course and characteristics of the tumor 
response to ECT.
ECT induces an early intense damage to the tumor 
cells. The histologic signs of cell injury (swollen cells with 
homogeneous eosinophilic cytoplasm, chromatin conden-
sation, less prominent nucleoli) can be detected as early as 
10 min after treatment. They increase progressively during 
the following days, leading finally to a complete destruction 
of tumor nodules that in our cases was evident 2 months 
after therapy. A distinctive sign of melanoma cell damage 
after ECT is the progressively increasing number of mul-
tinucleated syncytial cells. These cells may result from an 
in vivo electrofusion induced by EP, as demonstrated in an 
experimental tumor model in mice (B16 melanoma).20 In 
this model, syncytial cell formation was an early (1 h) event 
after EP, and was melanoma-specific, as it did not occur 
in normal tissue or in another tumor type (LPB fibrosar-
coma). Morphological and immunohistochemical evidence 
of apoptosis was detected in the multinucleated cells. In 
our model, we could detect the appearance of syncytial 
aggregations as early as 3 h after ECT, and multinucleated 
apoptotic (caspase-3 positive) cells were still present after 
1 month. The TUNEL reaction and the caspase-3 staining, 
hallmarks of apoptosis, paralleled the histological signs of 
damage, peaking at 3 and 10 days after ECT, then gradually 
reverting toward base levels. The consistency of histological 
and immunohistochemical findings strongly supports the 
assumption of an apoptotic cell death. In a mouse model, 
involving treatment of experimentally injected melanoma 
lines using an association of low electric field and chemo-
therapy, also a transient (3–4 h) apoptotic phase, as detected 
by morphologic (swollen cells with condensed nuclei) and 
immunohistochemical observations, was demonstrated. 
The apoptotic step was followed by massive necrosis of 
the tumors at 48–72 h.21 In rats, hepatocellular carcinoma 
nodules treated with ECT showed morphologic signs of 
apoptosis decreasing from day 3 to day 14. No sign of 
apoptosis was seen at day 21, when tumor nodules appeared 
completely necrotic.22 An in vitro study by Tounekti et al 
showed that the mechanisms of the cell death caused by 
bleomycin were closely related to the number of bleomycin 
molecules introduced into the cell cytoplasm. When only a 
few thousand molecules were internalized, cells displayed 
an arrest in the G2-M phase of the cell cycle paralleling the 
“mitotic death” seen after ionizing irradiation. By contrast, 
the introduction of high amounts of molecules into the cell 
cytoplasm by electropermeabilization induced events analo-
gous to those observed during apoptosis (cell shrinkage, 
membrane blebbing, reduced cell fluorescence, and inter 
nucleosomal DNA fragmentation), so bleomycin could be 
considered an apoptosis mimetic drug.18
An experimental model in mice, analogous to our thera-
peutic situation, was carried on by Mekid et al,23 and likewise, 
they observed two different cell death pathways in melanoma-
bearing mice treated with bleomycin and EP, depending on 
the bleomycin dose utilized. At low dose, a mitotic cell death 
pathway was characterized by the appearance of atypical 
mitoses (TUNEL and caspase-3 positive) followed by typical 
apoptotic cells. At high doses, a pseudoapoptotic pathway was 
detected, that is, the rapid appearance of apoptotic morpho-
logical changes due to the bleomycin-induced generation of 
double-strand DNA breaks without the intervention of the 
cell enzymatic processes. In the therapeutic setting, it is likely 
that different tumor cell death mechanisms are operating, 
nevertheless the positivity of caspase-3 staining indicates 
that at least a fraction of the tumor cells undergoes a true 
apoptotic process. 
Ischemic damage has been promoted as a possible mecha-
nism of cell damage after ECT. A transient decrease in blood 
Figure 3 Immunohistochemical characterization of the inflammatory infiltrate 
surrounding tumor cells at 1 month (A) CD8 and (B) Granzyme-B.
A B
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flow is a physiological reaction of the tissues exposed to elec-
tric pulses. Interestingly, it has been shown that in tumors the 
vasoconstriction (vascular lock) is much more longer than in 
normal tissues.24,25 These modifications in blood flow could be 
therapeutically advantageous, decreasing the drug wash-out 
in tumoral nodules. Moreover, damage to endothelial cells 
has been observed.10,17 ECT has been demonstrated to have 
direct vascular disrupting action on the tumor blood ves-
sels. A study by Markelc et al showed the in vivo response 
of tumor and normal blood vessels to ECT at a single blood 
vessel level. In the tumors treated with ECT, there was no 
blood flow detected even 24 h after the therapy, indicating that 
the cytotoxic effect of ECT on tumor endothelial cells prob-
ably destroys the tumor blood vessels, leading to ischemic 
death of the cells. In a clinical setting, this effect results in 
an immediate and prolonged cessation of bleeding followed 
by crust formation. Of outmost importance is also the fact 
that the normal blood vessels surrounding the tumor were 
not destroyed after ECT and retained their functionality after 
the therapy confirming that the selective action by ECT on 
tumor vasculature.25,26 
In the specimens of this study, vasodilation was observed 
as result of the acute inflammation, and neoangiogenesis in 
the late phases, but histologic sign of vascular damage was 
scant and limited to the endothelial cells and to fibrin deposi-
tion in the 3- and 10-day specimens.
Apoptotic cell destruction may favor the development 
of an antitumor immune response. Both enhanced exposure 
of tumor-associated antigens and better accessibility of 
immune cells to tumor antigens may explain this effect. 
In our study, the early appearance and the progressive 
increase of the inflammatory infiltrate, which mirrors the 
gradual reduction of the tumor mass, underscore the heavy 
participation of the immune-inflammatory system in the 
tissue events subsequent to ECT. The characterization of 
the inflammatory infiltrate showed a substantial presence 
of CD8+ lymphocytes that infiltrated and surrounded the 
tumor cells from the earliest phases to the late stages. 
Persistent CD8+ cells were present 2 months after ECT, 
when more tumor cells could not be detected. Expression 
of Granzyme-B, the lymphocytic cytotoxic protein that acti-
vates the apoptotic mechanism, was detected in the CD8+ 
cells. A NK cell response was also present, detectable as 
early as 3 h after treatment. No signs of participation of other 
immune cell types were found. Our observation is in line 
with previous experimental studies that showed infiltration 
of inflammatory cells 7 days after the third run of ECT in 
mice.27 In another study, a massive infiltration of T cells and 
macrophages into the tumor was appreciated at 48–72 h 
after low electric field-enhanced chemotherapy of melanoma 
in mice.21 An investigation focused on the analysis of the 
inflammatory infiltrate in tumor-bearing mice after ECT, 
demonstrating an early recruitment of antigen-presenting 
dendritic cells, followed by the later (72–96 h) appearance 
of CD8+ lymphocytes.28 Local infiltration and activation of 
epidermal (Langerhans cells) and dermal dendritic cells have 
been shown also in melanoma metastases after therapeutic 
ECT.12 In humans, the antitumor cytotoxic T lymphocyte 
responses against known tumor antigens were investigated 
by Andersen et al29 in melanoma patients over the course 
of IL-2-based ECT. The authors found a statistically sig-
nificant decline in the amount of tumor-specific T cells in 
peripheral blood during therapy, followed by a statistically 
significant reappearance of the T cells upon interruption 
of IL-2 administration. These data strengthen the notion 
that IL-2 adds to the capacity of activated T cells to leave 
the blood stream and home to the tumor site.  Molecular 
analyses of the clonotypic composition of responding T cells 
demonstrated that new clones emerged over the course of 
treatment. The authors suggest that the extensive tumor cell 
death elicited by the ECT may attract dendritic cells that 
capture exogenous tumor antigen, subsequently migrate 
to the draining lymph nodes and initiate T-cell responses 
against tumor antigens.29 Dendritic cells can efficiently 
prime melanoma-specific CD8+ lymphocytes, stimulating 
their migration to the inflamed skin.30 Even if a persistent 
inflammatory reaction was evident after ECT, with a massive 
participation of CD8+/Granzyme-B+ cells in the same areas 
where tumor cell death is evident, the present model does not 
allow to reach conclusive evidence of a contribution of these 
immune cell/tumor cell interactions to the activation of the 
apoptotic mechanisms and to the local tumor destruction. 
Pioneer studies investigated the participation of the immune 
system to ECT responses in experimental animal models, 
demonstrating that a normal immune system is required 
for the complete tumor eradication.31 The enhancement of 
the local and systemic antitumor effects by the combina-
tion of ECT with adjuvant immunotherapy substantiated 
these findings.32 Later, it was demonstrated that specific 
cytotoxic T-lymphocyte responses, as evaluated with the 
chromium radioisotope 51Cr release assay, can be induced 
in the spleen of mice after ECT treatment of experimental 
colorectal carcinoma. Tumor development from cancer cell 
reinjection was hampered in survived animals. Thus, ECT 
seems to confer protective immunity toward experimental 
tumor re-challenge.33 These results were confirmed in mel-
anoma-bearing mice that showed protection toward tumor 
reinjection after ECT treatment. This resistance could be 
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reversed with the immunosuppressive drug cyclosporin A. 
Furthermore, the splenocytes of cured animals show antitu-
mor activity in a Winn assay and increased level of several 
cytokines m-RNA expression (IL-2, IL-4, and IFNg)
.
21 Addi-
tional studies confirmed that repeated ECT sessions elicit 
tumor regression in immunocompetent mice inoculated 
with colon carcinoma cell lines. The same effect was not 
seen in nude mice, supporting once more the concept that 
an efficient immune response is required to obtain a com-
plete therapeutic effect.27,34 Finally, more findings showed 
that stimulation of dendritic cells with toll-like receptor-9 
ligands greatly enhances the systemic antitumor immune 
response after ECT and that this response is mediated by 
CD8+ lymphocytes, which are expanded and activated both 
locally (draining lymph nodes) and systemically (spleen).28
Conclusion
ECT is a very efficient local anticancer treatment for superfi-
cial lesions and possibly for deeper tumors. Although ECT is 
highly efficient on locally treated nodules, it appears to have 
no antitumor effects on nontreated distant nodules. Even 
though ECT shows immunostimulating properties through 
immunogenic cell death elicitation, the antitumor immune 
responses are not strong enough to destroy fully established 
distant tumors. Interestingly preliminary data sustain the use 
of ECT in association with systemic immune checkpoint 
inhibitors, such as anticytotoxic T lymphocyte-associated 
antigen-4 or antiprogrammed cell death protein 1 antibod-
ies. The combined concept of local therapy with systemic 
immune checkpoint inhibition is currently being studied in 
prospective clinical trials and has the potential to further 
improve the success of cancer immunotherapy.35,36
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